pharmaceutical
-
A Pseudo-Nonprofit Model for Psychedelic Clinical Trial Funding
Read more: A Pseudo-Nonprofit Model for Psychedelic Clinical Trial Funding
-
Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment
Read more: Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment
-
Book Review: ‘Drugs and the FDA: Safety, Efficacy, and the Public’s Trust’ by Mikkael A. Sekeres
Read more: Book Review: ‘Drugs and the FDA: Safety, Efficacy, and the Public’s Trust’ by Mikkael A. Sekeres
-
To Address the Overdose Epidemic, Tackle Pharma Industry Influence
Read more: To Address the Overdose Epidemic, Tackle Pharma Industry Influence
-
Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
-
“Stick to the Science”? FDA, Ethics, and Pandemics
Read more: “Stick to the Science”? FDA, Ethics, and Pandemics
-
What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)?
Read more: What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)?
-
How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
-
Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
-
What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?
Read more: What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?